Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
26%
Alzheimer's Disease
32%
Amyloid Plaque
32%
Androgen
32%
Bile Acid
96%
Bilirubin
19%
Cannabinoid
32%
Cannabis
25%
Clinical Trial
25%
Disease
43%
Drug Delivery System
32%
Dyslipidemia
12%
Endocannabinoid System
12%
Endocrine Disruptor
32%
Ether Lipid
12%
Farnesoid X Receptor
19%
Fatty Liver
12%
Fibroblast Growth Factor
64%
Fibroblast Growth Factor 1
75%
Fibroblast Growth Factor 19
55%
Fibroblast Growth Factor 21
81%
Gunn Rat
12%
Insulin Resistance
18%
Knockout Mouse
25%
Liver Disease
16%
Liver Injury
12%
Liver X Receptor
21%
Liver X Receptor Agonist
16%
Malignant Neoplasm
21%
Membrane Protein
32%
Metabolic Disorder
26%
Mouse
72%
Mouse Model
70%
N (2,3 Dihydroxypropoxy) 3,4 Difluoro 2 (2 Fluoro 4 Iodoanilino)benzamide
16%
Neonatal Hyperbilirubinemia
32%
Non Insulin Dependent Diabetes Mellitus
40%
Nonalcoholic Fatty Liver
100%
Peroxisome Proliferator Activated Receptor Alpha
12%
Phytol
19%
Phytosterol
16%
Preclinical Study
12%
Prevalence
17%
Receptor Agonist
12%
Sargassum
32%
Sex Hormone
12%
Side Effect
26%
Steatosis
51%
Steroid Hormone
32%
Thiazolidinedione
12%
Ursodeoxycholic Acid
32%
Biochemistry, Genetics and Molecular Biology
3T3-L1
9%
Adipocyte
32%
Alpha Oxidation
12%
Amyloid
32%
Bile Acid
51%
Bile Acid Metabolism
32%
Bile Composition
8%
Body Weight
22%
Cannabinoid
32%
Cannabis Use
25%
Comorbidity
16%
Drug Mechanism
16%
Endocannabinoid System
12%
Energy Metabolism
22%
Ether Lipid
12%
FGF1
20%
FGF19
16%
FGF21
16%
Fibroblast Growth Factor
64%
GALNT2
32%
Gene Expression
32%
Glucose Transport
32%
Glucose Transporter
9%
Glycosylation
32%
Homeostasis
48%
Insulin Resistance
22%
Isoform
12%
Knockout Mouse
30%
Life Expectancy
16%
Lipid
15%
Lipid Liver Level
32%
Lipid Metabolism
35%
Liver X Receptor
32%
Liver X Receptor Beta
9%
MAPK Signaling
16%
Membrane Protein
32%
Messenger RNA
19%
Metabolic Pathway
29%
Metabolic Regulation
32%
Metabolite
12%
Mouse
70%
Mouse Model
38%
Peroxisome
25%
Peroxisome Proliferator-Activated Receptor Alpha
12%
Phytosterol
13%
Polypeptide N-Acetylgalactosaminyltransferase
32%
Prevalence
22%
Receptor Agonists
13%
Sargassum
32%
Signal Transduction
16%
Keyphrases
Adverse Effects
12%
Allreduce
10%
Amyloid Plaque Load
32%
Bile Acids
32%
Bilirubin
19%
Cirrhosis
9%
Conventional Phototherapy
6%
Cue-induced Reinstatement
7%
Drug-induced Reinstatement
7%
Effective Treatment
32%
Ethyl
6%
Exchange Transfusion
6%
Farnesoid X Receptor
19%
Fibroblast Growth Factor 1 (FGF1)
32%
Fibroblast Growth Factor 21 (FGF21)
32%
Gunn Rat
12%
GW4064
6%
Hepatic Steatosis
8%
Humanized Mice
6%
Indirect Activation
6%
Insulin Resistance
8%
Kernicterus
6%
Lipid Catabolism
8%
Liver Disease
9%
LY2405319
6%
Mouse Model
32%
Neonatal Hyperbilirubinemia
32%
Neonatal Jaundice
6%
Neurological Injury
6%
NGM282
6%
Non-alcoholic Fatty Liver Disease (NAFLD)
46%
Nonalcoholic Steatohepatitis
32%
Obeticholic Acid
6%
PD0325901
32%
Pegbelfermin
38%
PEGylated
32%
Peroxisome Proliferator-activated Receptor
12%
Postnatal Day
6%
Preventive Treatment
6%
Pristanic Acid
12%
Protein Level
6%
Recombinant
16%
Sargassum Fusiforme
32%
Saringosterol
16%
Steatohepatitis
32%
Steatosis
32%
Thiazolidinediones
12%
Treatment Options
6%
Triclocarban
8%
Ursodeoxycholic Acid
32%
